MedTrace Logo

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

NCT06122896 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2025-06-03

No results posted yet for this study

Summary

The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

Conditions

Interventions

OTHER

Screening Blood Tests

Carbohydrate antigen (CA) 19-9, and Hemoglobin A1C (HbA1c) per standard-of-care.

DIAGNOSTIC_TEST

Endoscopic Ultrasound

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

COMBINATION_PRODUCT

Magnetic Resonance Imaging

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

COMBINATION_PRODUCT

Magnetic Resonance Cholangiopancreatography

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

Sponsors & Collaborators

Principal Investigators

  • Matthew Yurgelun, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2040-10-31
Completion
2041-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122896 on ClinicalTrials.gov